"Our number one priority as a company right now is to bring to market a Pan-respiratory annual booster vaccine, which we plan to always customize and upgrade," Chief Executive Officer Stéphane Bancel said during Moderna's R&D day.

The company provided updates on its ongoing mid-stage trial testing its authorized COVID-19 vaccine in children aged 6 months to less than 12 years.

Moderna's vaccine, which received its emergency authorization for people aged 18 and older in the United States in December, is currently under an FDA review for use in adolescents.